

Registration : www.meeting-com.ch

Final Program




46th Annual Meeting Swiss Society of Nephrology

Interlaken, Kursaal
December 4-5, 2014

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie
Società Svizzera di Nefrologia
Swiss Society of Nephrology

NEPHRO
SWISS SOCIETY OF NEPHROLOGY
www.swissnephrology.ch

Early Symposia : December 3, 2014
Basics in Nephrology
Pflege in der Nephrologie



Die Kunst der sHPT-Kontrolle

Durch die gleichzeitige Senkung aller drei biochemischen Schlüsselparameter (PTH, Kalzium und Phosphat),^{1,2} verbessert Mimpara® die Kontrolle des sekundären Hyperparathyreoidismus (sHPT).³⁻⁵

Mimpara®
cinacalcet

Mimpara® (Cinacalcet): Calcimimetikum. Es senkt direkt die Parathormonspiegel indem es die Empfindlichkeit des Kalziumsensitiven-Rezeptors auf extrazelluläres Kalzium erhöht. Die Reduktion der Parathormonspiegel ist mit einer gleichzeitigen Abnahme der Serumkalziumspiegel verbunden. **Indikationen:** Zur Behandlung der sekundären Hyperparathyreoidismus bei dialysepflichtigen Patienten mit chronischer Nierenerkrankung. Zur Behandlung der Hyperkalzämie bei Patienten mit Nebenschilddrüsenkarzinom und bei Patienten mit primärem Hyperparathyreoidismus, bei denen die Entfernung der Nebenschilddrüse keine Behandlungsmöglichkeit darstellt. **Dosierung/Anwendung:** Mimpara® wird oral gegeben. PHPT: Empfohlene Anfangsdosis für Erwachsene ist 30mg zweimal täglich. Die Dosis von Mimpara® kann ausgehend von zweimal täglich 30mg, alle 2-4 Wochen auf 60mg zweimal täglich, 90mg zweimal täglich, bis zu 90mg 3-4x täglich erhöht werden, abhängig von der Normalisierung der Serumkalziumspiegel. Der Serumkalziumspiegel sollte innerhalb der ersten Woche nach Beginn der Therapie oder Dosisanpassung von Mimpara® gemessen werden. Nachdem die Erhaltungsdosis festgelegt wurde, sollte der Serumkalziumspiegel alle 2-3 Monate gemessen werden. sHPT: Empfohlene Anfangsdosis für Erwachsene ist 30mg einmal täglich. Alle 2-4 Wochen aufzutitrieren, bis zur Erreichung des iPTH Zielwert von 150-300 pg/ml. Serumkalziumspiegel während der Titrationsphase häufig, in der Erhaltungsdosis monatlich kontrollieren. Parathormon 1-4 Wochen nach Therapiebeginn oder Dosisanpassung messen, in der Erhaltungsdosis alle 1-3 Monate kon-

trollieren. **Kontraindikationen:** Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe gemäss Zusammensetzung. **Warnhinweise und Vorsichtsmassnahmen:** Anfälle: Die Schwelle für die Auslösung von Anfällen ist bei einer signifikanten Reduktion der Serumkalziumspiegel herabgesetzt. Serumkalzium: Da Cinacalcet die Serumkalziumspiegel erniedrigt, sollten Patienten auf Hypokalzämiesymptome überwacht werden. Fälle von QT-Verlängerung und ventrikulärer Arrhythmie sekundär zu einer Hypokalzämie wurden angegeben. Bei mit Mimpara® behandelten Patienten, einschliesslich pädiatrischen Patienten, wurde im Zusammenhang mit Hypokalzämie von lebensbedrohlichen Ereignissen und Todesfällen berichtet. Der Serumkalziumspiegel sollte innerhalb von 1 Woche nach dem Beginn der Behandlung oder einer Dosisanpassung von Mimpara® gemessen werden. Wenn die Erhaltungsdosis eingestellt ist, sollte das Serumkalzium ungefähr monatlich bestimmt werden. Bei Hypokalzämie sollten geeignete Massnahmen gemäss vollständiger Fachinformation ergriffen werden. Falls die PTH-Spiegel bei mit Mimpara® behandelten Patienten tiefer als die unteren empfohlenen Zielwerte sinken, sollten die Dosierung der Vitamin-D-Sterole oder von Mimpara® reduziert bzw. die Behandlung abgebrochen werden. **Interaktionen:** Ketoconazol: Cinacalcet wird teilweise durch das Enzym CYP3A4 metabolisiert. Die gleichzeitige Verabreichung von Ketoconazol resultiert in einer ungefähr 2fachen Erhöhung der Cinacalcet-Spiegel. Arzneimittel, die durch CYP2D6 metabolisiert werden: Es konnten keine Interaktionen beobachtet werden, wenn

Mimpara® gleichzeitig mit folgenden Arzneimitteln zusammen gegeben wurde: Sevelamer, Kalziumkarbonat, Warfarin und Pantoprazol. **Unerwünschte Wirkungen:** Immunsystem: Häufig: Hypersensitivitätsreaktionen. Stoffwechsel und Ernährung: Häufig: Anorexie, verminderter Appetit, Hypokalzämie. Nervensystem: Häufig: Krampfanfälle, Schwindel, Parästhesien, Kopfschmerzen. Gefässe: Häufig: Hypotonie. Atmungsorgane: Häufig: Infektion der oberen Atemwege, Dyspnoe, Husten. Gastrointestinaltrakt: Sehr häufig: Übelkeit, Erbrechen. Haut: Häufig: Rash. Muskelskelettsystem: Häufig: Myalgie, Muskelspasmen. Allgemeine Erkrankungen: Häufig: Asthenie. Untersuchungen: Häufig: Hypokalzämie, Hyperkalzämie, verringerte Testosteronwerte. **Packungen:** Filmtabletten mit 30, 60 und 90mg Mimpara® in Blisterpackungen à 28 Stück. Ausführliche Angaben entnehmen Sie bitte der Fachinformation unter www.swissmedinfo.ch. **Zulassungsinhaber:** Amgen Switzerland AG, Zug. **Verkaufskategorie B.** MN-CHE-AMG-2011-September-P

Referenzen:
1. Messa P et al. Clin J Am Soc Nephrol 2008; 3(1): 36-45.
2. Frazão JM et al. Clin Nephrol 2011; 76(3): 233-243.
3. Urea-Torres PA et al. Nephrol Dial Transplant 2013; 28(1): 146-152. 4. The EVOLVE trial investigators. N Engl J Med 2012; 367(26): 2482-2494. 5. Block G et al. Kidney Int. 2010; 78: 578-589.

AMGEN Switzerland AG, Dammstrasse 21
6301 Zug, www.amgen.ch

Invitation 2014

Dear Colleagues, Friends and Guests

Meeting in Interlaken in December has become a great tradition for all Swiss Nephrologists. We are proud to invite you to the 46th annual meeting of the Swiss Society of Nephrology.

This year, we have chosen to condense the meeting into two full days – Thursday and Friday – to make it easier for all of you to attend the entire meeting. As in previous years, the continuous medical education (CME) and the Nephrology Nurses' symposia will be held on Wednesday afternoon.

We decided to dedicate this years' congress to "real world" nephrology.

Key subjects therefore include:

- Prevention of vascular calcification and stroke in patients with chronic kidney disease
- The role of renal artery interventions: Revascularisation, denervation or what have you else
- The roles of (old and new) anticoagulants in renal disease
- The value of blood pressure measurements on hemodialysis
- What to do after transplant failure
- The Pros and Cons of a Living Donor Exchange Program

We also look forward to several State of The Art lectures on pathophysiological concepts which may importantly shape how we treat patients in the future. These include:

- Inflammation and the role of inflammasome
- Glomerular permeability and the glycocalyx
- Cilia and the kidneys

Oral and poster presentations, NCCR slots (Swiss National Centres of Competence in Research) and satellite symposia will cover the entire range of nephrology. The CME course on Wednesday will be dedicated to Genetics for the Clinical Nephrologist.

The final symposium on Friday afternoon has been labelled "The really tough cases: who cares and who pays?" Starting with a few short case reports, an interdisciplinary panel including nephrologists, social workers, and representatives from politics and insurance companies will discuss (often) unsolved issues of "difficult" patients, e.g. immigrants, patients falling through the social net) and the special situation, where the choice of dialysis mode may have huge implications.

As Congress presidents of the SGN-SSN 2014, we look forward to meeting all of you in Interlaken in December! It will be a great opportunity to share your research, to exchange views, and to meet old and new friends.

A. Bock

Prof. Dr. Andreas Bock

T. Neuhaus

Prof. Dr. Thomas J. Neuhaus

Table of contents

Invitation 2014	3
Organization	5
General information	6
Program at a glance	9
Scientific Program – Pflege in der Nephrologie	12
Scientific Program – Basics in Nephrology	13
Scientific Program	14
Poster presentations	34
City map of Interlaken	47
Exhibitors	49
Sponsored symposia in alphabetical order	50
Congress Dinner	52
SGN-SSN congress 2015	53
Sponsors	54

Organization

Congress Presidents	Andreas Bock, Aarau Thomas J. Neuhaus, Luzern
Scientific Committee	Olivier Bonny, Lausanne Olivier Devuyst, Zürich Andreas Fischer, Luzern Stefan Schaub, Basel Stephan Segerer, Zürich
Board of the SGN-SSN	President Jürg Steiger, Universitätsspital, Basel President-elect Pierre-Yves Martin, HUG, Genève Past President François Verrey, Physiolog. Institut Universität, Zürich Secretary Olivier Bonny, CHUV, Lausanne Treasurer Patrick Wilson, Hôpital du Jura, Delémont FMH-Delegate Felix Brunner, Basel Paediatric Nephrologist Thomas J. Neuhaus, Kinderspital LUKS, Luzern Dialysis Committee Denes Kiss, Kantonsspital, Liestal Assessors Luca Gabutti, Ospedale Regionale, Locarno Daniel Fuster, Inselspital Universitätsspital, Bern Andreas Bock, Kantonsspital, Aarau

General information

Congress venue	Congress Centre Kursaal Interlaken Strandbadstrasse 44 3800 Interlaken		
Registration & congress secretariat	Meeting.com Congress organisation Rue des Pâquis 1, CP 100, CH-1033 Cheseaux-sur-Lausanne Online registration on: www.meeting-com.ch T +41 21 312 9261 – F +41 21 312 9263 – E info@meeting-com.ch Onsite registration also possible (onsite fee)		
Registration fee for congress	Early fee (before Oct. 31, 2014)	Late fee (Nov. 1-27, 2014)	Onsite fee (From Nov. 28, 2014)
Member SGN-SSN	CHF 180.00	CHF 220.00	CHF 250.00
Non-member	CHF 230.00	CHF 270.00	CHF 300.00
Trainees / Residents / Students*	CHF 130.00	CHF 170.00	CHF 200.00
<i>NCCR-Member</i>	<i>CHF 130.00</i>	<i>CHF 170.00</i>	<i>CHF 200.00</i>
	<i>Online registration under www.nccr-kidney.ch / News&Events</i>		

The registration fee includes: access to the scientific sessions, congress documents and lunches. The Congress Dinner is not included and has to be booked separately when registering (CHF 70.00). Places are limited and a reservation is required.

*In order to benefit from the reduced fee, students or residents are required to send a document confirming their status to the SGN-SSN 2014 Congress Management by fax or email within 7 days from the date of registration.

Registration fee for parallel symposia	Early fee (before Oct. 31, 2014)	Late fee (Nov 1-27, 2014)	Onsite fee (from Nov. 28, 2014)
Basics in Nephrology	CHF 80.00	CHF 100.00	CHF 120.00
Pflege in der Nephrologie	CHF 60.00	CHF 80.00	CHF 100.00

Separate registration is required using the online-registration on www.meeting-com.

Payment Upon registration you will receive a confirmation by email together with the banking details for the payment. Payment by credit card upon registration possible.

General information

Cancellation	Written notification is required for all cancellations and changes. Cancellations of registrations should be sent to the Congress Secretariat. Before October 31, 2014, 50% refund of the registration fee. Thereafter no refunding.
Industrial exhibition	An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors.
Hotel booking	Hotel reservation possible online on www.meeting-com.ch when registering.
Congress management	Meeting.com Congress Organisation Mrs Sabine Gisler Rue des Pâquis 1, CP 100, 1033 Cheseaux-sur-Lausanne T +41 21 312 9161, F +41 21 312 9263 sabine.gisler@meeting-com.ch , www.meeting-com.ch
Abstracts	The abstracts must be submitted until September 14, 2014, only via Internet on: www.swissnephrology.ch The Scientific Committee will select a number of abstracts which will be presented as oral presentations. Speaking time: 8 min and 2 min discussion. The abstracts accepted as poster will be presented in the poster exhibition. Dimensions of posters: height 120 cm and width 90 cm. The two highest rated posters will receive the SGN-SSN Poster Award during the Congress Dinner on December 4, 2014.
Confirmation	Scientific contributions (oral presentations and posters) will be reviewed and confirmed by e-mail by beginning of October, 2014. Authors presenting an accepted paper or poster must register to attend the meeting and pay the appropriate registration fee.

General information

Credits

Credits points will be given by the following societies:

SGN-SSN Congress, December 4-5, 2014

SGN-SSN: 12 credit points

SGIM/SGAM: 8 credit points

Basics in nephrology, December 3, 2014

SGN-SSN: 4 credit points

SGIM/SGAM: 4 credit points

Language

Lectures in English, discussion in German, French or English.
The Symposium «Pflege in der Nephrologie» will be held in German.

Program at a glance

Wednesday, December 3, 2014

	Special Satellite Symposium Pflege in der Nephrologie	Special CME Symposium Basics in Nephrology
Time	Room A	Room B
12.30-13.30	Registration	
13.30-15.30	Pflege in der Nephrologie	Plenary session
15.30-16.00	Kaffeepause	Coffee break
16.00-18.00	Pflege in der Nephrologie	Plenary session
18.00	Ende des Symposiums	End of Basics in Nephrology Course

Program at a glance

Thursday, December 4, 2014

Time	Room A	Room B
08.00-10.00	Registration	
10.00-10.05	Welcome Address	
10.05-11.00	State of the Art Lectures	
11.00-11.30	Coffee break – Visit of the Exhibition	
11.30-12.15	Oral Parallel Presentations Clinical Nephrology	Oral Parallel Presentations Basic Science / Genetics
12.15-12.30	Break	
12.30-13.15	Satellite Lunch Symposium Sponsored by BAXTER	Satellite Lunch Symposium Sponsored by FRESENIUS
13.15-14.00	Standing lunch at the Exhibition – Poster Viewing	
14.00-15.00	Parallel Symposium Chronic Kidney Disease	Parallel Symposium Transplantation
15.00-15.30	Coffee break – Visit of the Exhibition – Poster Viewing	
15.30-16.15	Satellite Symposium Sponsored by NOVARTIS	
16.15-16.30	Short Break	
16.30-17.30	Oral Parallel Presentations Transplantation Gil Thiel Lecture	Oral Parallel Presentations NCCR / Experimental Nephrology Mini-Lecture
17.30-19.00	Main Poster Session – Apéro	
From 19.30	Congress Dinner – Poster prize awards	

Program at a glance

Friday December 5, 2014

Time	Room A	Room B
07.00-08.00	Registration	
08.00-09.30	General assembly SGN-SSN	
09.30-09.45	SGN-SSN Publication Award 2014	
09.45-10.00	Break	
10.00-11.00	State of the Art Lectures	
11.00-11.30	Coffee Break – Visit of the Exhibition – Poster Viewing	
11.30-12.15	Satellite Symposium Sponsored by VIFOR	Satellite Symposium Sponsored by BAXTER
12.15-12.30	Break	
12.30-13.15	Satellite Lunch Symposium Sponsored by AMGEN	Satellite Lunch Symposium Sponsored by LABORATOIRE BICHSEL
13.15-14.00	Standing lunch at the Exhibition – Poster Viewing	
14.00-15.00	Oral Parallel Presentations Hypertension/Minerals/Electrolytes Mini-Lecture	Oral Parallel Presentations Dialysis Mini-Lecture
15.00-15.30	Coffee Break – Visit of the Exhibition	
15.30-16.30	Final Symposium: The really tough cases Who cares and who pays?	
16.30	Farewell	

Special Satellite Symposium:

Pflege in der Nephrologie / Soins en Néphrologie

(Symposiumssprache: Deutsch)

Vorsitz:	<i>Stephan Segerer, Zürich</i>
Ab 12.30	Registration
Vorsitz:	<i>Patrick Witschi, Zürich</i>
13.30-14.30	Podiumsdiskussion zur Ausbildung in der Pflege Nephrologie
<i>13.30-13.35</i>	Einführung <i>Patrick Witschi, Zürich</i>
<i>13.35-13.55</i>	<i>Der Weg zur Zulassung HFP (Höhere Fachschule Pflege) Nephrologie-Pflege</i>
<i>13.55-14.05</i>	CAS (Certificate of Advanced Studies) Nephrologie Pflege <i>Ursina Baumgartner, Zürich</i>
<i>14.05-14.30</i>	Roundtable Diskussion <i>Patrick Witschi, Zürich; Ursina Baumgartner, Zürich; Ursula Dietrich, Bern; Claudia Studer, Zürich; Annemarie Bieri, Aarau</i>
14.30-15.00	Pflegesprechstunde für Patienten mit chronischer Niereninsuffizienz und ihre Angehörigen – ein interdisziplinäres Projekt <i>Gisela Rütli, Bern</i>
15.00-15.30	Lean Management und Workshop <i>Philipp Meyer Hänel, Zürich</i>
15.30-16.00	Kaffeepause
Vorsitz:	<i>Stephan Segerer USZ, Zürich</i>
16.00-16.30	Pflegeinterventionen bei psychischen Krankheiten: Psychose, Bipolare Störung und Borderline Störung <i>Jan van Luijk, Aadorf</i>
16.30-17.30	Wege zum perfekten Knopfloch
<i>16.30-16.50</i>	Theoretische Einleitung und Literaturübersicht <i>Walter Brunner, Chur</i>
<i>16.50-17.00</i>	Das Zürcher Knopfloch <i>Robert Kistler, Zürich</i>
<i>17.00-17.10</i>	Das Bieler Knopfloch <i>Martin Stuber, Biel</i>
<i>17.10-17.30</i>	„Knopfloch – Diskussion“
17.30-18.00	Ethische Grenzfälle in der Nephrologie <i>Tatjana Weidmann, Zürich</i>
18.00	Ende des Symposiums

Satellite CME Symposium: Basics in Nephrology

Genetics for the nephrologist: What you need to know in 2014

Chair:	<i>Thomas J. Neuhaus, Luzern</i>
From 12.30	Registration
13.30-14.00	Genetic analysis in 2014 <i>Benno Röthlisberger, Aarau</i>
14.00-14.30	Nephrotic Syndromes <i>Paloma Parvex, Genève</i>
14.30-15.00	Polycystic Kidney Diseases <i>Olivier Devuyst, Zürich</i>
15.00-15.30	Tubulopathy: Proximal tubules <i>Thomas J. Neuhaus, Luzern</i>
15.30-16.00	Coffee Break
16.00-16.30	Hereditary Hypertension <i>Olivier Bonny, Lausanne</i>
16.30-17.00	Tubulopathies: Distal tubules <i>Thomas J. Neuhaus, Luzern</i>
17.00-17.30	Atypical haemolytic uraemic syndromes <i>Giuseppina Spartà, Zürich</i>
17.30-18.00	Emerging therapies for TSC and PKD <i>Andreas Serra, Zürich</i>
18.00	End of Basics in Nephrology Course

Thursday, December 4

Swiss Society of Nephrology Congress

From 08.00	Registration	
10.00	Opening of the 46th Annual Meeting of the Swiss Society of Nephrology	Room A
10.00-10.05	Welcome Address Andreas Bock, Aarau ; Thomas J. Neuhaus, Luzern	
10.05-11.00	State of The Art Lectures <i>Chairs: Andreas Bock, Aarau and Thomas J. Neuhaus, Luzern</i>	
10.05-10.30	How to prevent ESRD related calcification in 2014 Jürgen Floege, Aachen (D)	
10.30-11.00	Burning kidneys - the inflammasome in renal inflammation Hans-Joachim Anders, München (D)	
11.00-11.30	Coffee Break – Visit of the Exhibition	Exhibition space
11.30-12.15	Oral Parallel Presentations Clinical Nephrology <i>Chairs: Andreas Fischer, Luzern and Daniel Varga, Zug</i> 4 oral presentations	Room A
	Basic Science / Genetics <i>Chairs: Olivier Devuyst and Giuseppina Spartà, Zürich</i> 4 oral presentations	Room B
12.15-12.30	Break	

Oral communications

Oral Parallel Presentations		
11.30-12.15	Clinical Nephrology <i>Chairs: Andreas Fischer, Luzern and Daniel Varga, Zug</i>	Room A
OC 01	A Registry of Patients with Autosomal Dominant Tubulointerstitial Kidney Disease (NCCR project) Eric Olinger¹ , Karin Dahan ² , Olivier Bonny ³ , Olivier Devuyst ¹ ¹ Zürich, ² Gosselies / BE, ³ Lausanne	
OC 02	Long term outcome of membranous glomerulonephritis associated with anti-PLA2R antibodies Helmut Hopfer¹ , Thomas Menter ¹ , Elion Hoxha ² , Michael Mihatsch ¹ , Felix Burkhalter ¹ ¹ Basel, ² Hamburg / DE	
OC 03	Sleep quality decreases with declining GFR in early stages of chronic kidney disease Adam Ogna, Valentina Forni Ogna , José Haba Rubio, Nadia Tobback, Murielle Bochud, Raphaël Heinzer Lausanne	
OC 04	A urine peptidome-based score accurately predicts the risk of reaching ESRD in ADPKD patients Andreas Kistler¹ , Martin Pejchinovski ² , Harald Mischak ² , Arlene Chapman ³ ¹ Zürich, ² Hannover / DE, ³ Atlanta / US	

As individual as your patients

PD therapy tailored to patients' needs

Visit us at
SGN-SSN 2014



Experience the *sleep.safe* harmony on
www.sleepsafe-harmony.com



Oral communications

Oral Parallel Presentations

11.30-12.15


Basic Science / Genetics

Room B

Chairs: Olivier Devuyst and Giuseppina Spartà, Zürich

- OC 05 **Correlation of Transcriptome Sequencing Data from Formalin-Fixed, Paraffin-Embedded vs. RNAlater® stored Kidney Biopsies**
Hans-Peter Marti¹, Øystein Eikrem¹, Christian Beisland¹, Karin Hjelle¹, Arnar Flatberg², Andreas Scherer³, Heidrun Vethe¹, Trude Skogstrand¹, Sabine Leh¹, Vidar Beisvåg²
¹Bergen / NO, ²Trondheim / NO, ³Kontiolahti / FI
- OC 06 **Effect of SGLT-2 inhibitor Dapagliflozin on Cystic Disease Progression in PCK Rats with Autosomal Recessive Polycystic Kidney Disease (ARPKD)**
Sarika Kapoor, Daniel Rodriguez, Meliana Riwanto, Ilka Edenhofer, Katharyn Mitchell, Colin Schwarzwald, Stephan Segerer, Rudolf P Wüthrich
 Zürich
- OC 07 **Calciprotein Particles Induce Calcification of Vascular Smooth Muscle Cells In vitro**
Parisa Aghagolzadeh¹, Bijarnia Rakesh Kumar¹, Prakash Chandak¹, Matthias Bachtler¹, Edward R. Smith², Andreas Pasch¹
¹Berne, ²Melbourne / AU
- OC 08 **The sodium/proton exchanger NHA2 is a novel regulator of sodium and calcium homeostasis in the distal convoluted tubule**
Manuel Anderegg¹, Giuseppe Albano¹, Christine Deisl¹, Ganesh Pathare¹, Johannes Loffing², Alain Vandewalle³, Daniel Fuster¹
¹Berne, ²Zürich, ³Paris / FR

Individualized Therapy
because every patient is different



Lunch Symposium

BRINGING THE BENEFITS OF HIGH DOSE HAEMODIALYSIS HOME

Thursday, December 4, 2014, 12.30-13.15 – Theatersaal (Room A), Kursaal Interlaken

Chair: **Prof. Dr. Dominik Uehlinger**, Inselspital Bern

- **Clinical Benefits of High-Dose Haemodialysis**
Dr. Tom Cornelis, Maastricht University Medical Center, Maastricht
- **How to run a successful Home Dialysis Program**
Dr. Eero Honkanen, Helsinki University Central Hospital, Helsinki

Thursday, December 4

12.30-13.15

Satellite Lunch Symposia

Sponsored by BAXTER

Bringing the Benefits of High-dose Hemodialysis Home with a Novel System

Chair: Dominik Uehlinger, Bern

1. **Clinical Benefits of High-Dose Hemodialysis**
Tom Cornelis, Maastricht (NL)
2. **How to run a successful Home Dialysis Program**
Eero Honkanen, Helsinki (FI)

Room A



Sponsored by FRESENIUS

New Perspectives in Phosphate Binding
Angel M.L. de Francisco, Spain (E)

Room B



13.15-14.00

Standing Lunch at the Exhibition – Poster Viewing

Exhibition space

14.00-15.00

Parallel Symposia

14.00-15.00

Symposium Chronic Kidney Disease

Chairs: Daniel Ackermann and Robert Kalicki, Bern

Room A

14.00-14.30

Preventing stroke in patients with chronic kidney disease and atrial fibrillation: Benefits and risks of old and new oral anticoagulants
Wolf-Rüdiger Schäbitz, Bielefeld (D)

14.30-15.00

Revascularisation of renal artery stenosis: Any indications left?
Philip Kalra, Salford and Manchester (UK)

14.00-15.00

Symposium Transplantation

Chairs: Stefan Schaub, Basel and Thomas Müller, Zürich

Room B

14.00-14.35

A Swiss Living Donor Exchange Program: Pros and Cons
Advantages: Karine Hadaya, Genève
Limitations: Michael Dickenmann, Basel

14.35-15.00

Optimal Management after Transplant Failure
Georg Böhmig, Wien (A)

15.00-15.30

Coffee Break – Visit of the Exhibition – Poster Viewing

Exhibition space



Confidence and Engagement

More than 30 years
of experience in Transplantation



INVITATION NOVARTIS SYMPOSIUM

04. December 2014 15:30–16:15 h


Impact of humoral alloimmunity vs. CNI nephrotoxicity on kidney transplant long-term outcomes

Chair: Prof. Dr. Manuel Pascual, Lausanne

Speakers: Dr. Alexander Loupy, Paris

Dr. Federico Oppenheimer, Barcelona

Thursday, December 4

15.30-16.15	Satellite Symposium Sponsored by NOVARTIS Impact of humoral alloimmunity vs CNI nephrotoxicity On kidney transplant long-term outcomes Chair: Manuel Pascual, Lausanne Alexander Loupy, Paris (F) Federico Oppenheimer, Barcelona (E)	Room A 
16.15-16.30	Short Break	
16.30-17.30	Oral Parallel Presentations	Room A
16.30-17.15	Transplantation Chairs: Patrizia Amico, Basel and Dela Golshayan, Lausanne 4 oral presentations	
17.15-17.30	Gil Thiel Lecture Risks of Living Donation Jürg Steiger, Basel	
16.30-17.15	NCCR / Experimental Nephrology Chairs: François Verrey and Nilufar Mohebbi, Zürich 4 oral presentations	Room B
17.15-17.30	Mini-Lecture Serum Calcification Propensity – from Research to Clinical Practice Andreas Pasch, Bern	
17.30-19.00	Main Poster Session – Apéro	Poster Area
19.30	Congress Dinner – Poster prize awards	Room B / Ballsaal

Urocit®

Rezidivprophylaxe des Nierensteins.¹



Kassenzulässig (BAG LIM)



- Wirksam u.a. bei Kalziumoxalat-, Kalziumphosphat- und Harnsäuresteinen²
- Abnahme der Steinbildungsrate bei 94% und komplette Remission bei 72% der Patienten³
- Kontinuierliche und verzögerte Freisetzung der Wirksubstanz dank WAX-MATRIX-System¹

Urocit® Tabletten **Z:** Kalii citras 1080 mg (10 mEq), Tabletten. **I:** Zur Alkalisierung des Harnes bei Patienten mit Nierensteinen in der Anamnese, zur Rezidivprophylaxe. **D:** Im Allgemeinen ist für die Anhebung des Urin-pHs auf einen Wert von 6–7 eine Dosis von 30–60 mEq/Tag erforderlich. **KI:** Hyperkalämie, Patienten mit erhöhtem Risiko für eine Hyperkalämie, beeinträchtigter Magendarmtransit, Ösophagus- bzw. Darmobstruktion oder -strikturen, Magen-Darm-Ulzera, aktive Harnwegsinfektion, eingeschränkte Nierenfunktion (GFR < 0.7 ml/kg/min), Komedikation mit kaliumsparenden Diuretika oder ACE-Hemmern. **VN:** Ausreichende Flüssigkeitszufuhr. Vor Therapiebeginn Elektrolyte im Serum bestimmen und Nierenfunktion kontrollieren. Bei Herzinsuffizienz oder anderen schweren Myokardschädigungen möglichst nicht anwenden. Vorsicht bei Myotonia congenita. **UW:** Häufig gastrointestinale Störungen, die weitgehend vermieden werden können, wenn das Präparat mit genügend Flüssigkeit eingenommen wird. **IA:** Kaliumsparende Diuretika, ACE-Hemmer, nicht-steroidale Antiphlogistika, periphere Analgetika, Digitalisglykoside, aluminiumhaltige Präparate, Präparate, die eine Verlangsamung der gastrointestinalen Transitzeit bewirken (wie z. B. Anticholinergika). **P:** Urocit® 100 Tabletten, Abgabekategorie B, Kassenzulässig (BAG LIM). Ausführliche Informationen siehe www.swissmedinfo.ch **Referenzen:** 1. Urocit® (Kaliumcitrat): aktuelle Fachinformation auf www.swissmedinfo.ch 2. Tiselius HG et al. Guidelines on Urolithiasis. European Association of Urology. Update March 2008. 3. Robinson MR et al. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol. 2009;181(3):1145-50.

Zulassungsinhaber: Pro Farma AG, Lindenstrasse 12, CH-6340 Baar, www.profarma.ch



Oral communications

Oral Parallel Presentations

16.30-17.15

Transplantation

Room A

Chairs: Patrizia Amico, Basel and Dela Golshayan, Lausanne

- OC 09 **Calcification propensity after kidney donation: a one year prospective study**
Sophie de Seigneux¹, Belen Ponte¹, Karine Hadaya¹, Pierre-Yves Martin¹, Andreas Pasch²
¹Geneva, ²Berne
- OC 10 **Final Results from the Long-term Extension (LTE) of the Belatacept Phase 2 Study in Kidney Transplantation**
Flavio Vincenti¹, Christian Larsen², Josep Grinyó³, Ferdinand Mühlbacher⁴, Gilles Blancho⁵, Gerrit Grannas⁶, Ulf Meier-Kriesche⁷, Bernard Charpentier⁸
¹San Francisco / US, ²Atlanta / US, ³Hospitalet de Llobregat / ES, ⁴Vienna / AT, ⁵Nantes / FR, ⁶Hannover / DE, ⁷New York / US, ⁸Le Kremlin-Bicêtre / FR
- OC 11 **Why are potential living kidney donors declined?**
Dimitrios Tsalis¹, Aurelia Schnyder, Wolfgang Ender, Jutta Thierbach, Urs Stillhard, Isabelle Binet
 St. Gallen
- OC 12 **The C1q-binding assays and clinical outcomes in kidney transplantation**
Gideon Hönger¹, Helmut Hopper¹, Stefan Schaub¹, Robert Liwski², Patrizia Amico¹
¹Basel, ²Halifax / CA

Individualized Therapy
because every patient is different



artis
physio

Satellite Symposium

INDIVIDUALIZATION OF HEMODIALYSIS THERAPY

Friday, December 5, 2014, 11.30-12.15

Ballsaal (Room B), Kursaal Interlaken

Speaker: **Prof. Dr. Antonio Santoro**
University Hospital of Bologna, Bologna

Chair: **Prof. Dr. Michel Burnier**
CHUV, Lausanne

Oral communications

Oral Parallel Presentations

16.30-17.15 NCCR / Experimental Nephrology
Chairs: François Verrey and Nilufar Mohebbi, Zürich

Room B

- OC 13 **Fetal hypoxia induces ectopic Fetuin A expression in renal tubular cells**
Stefan Rudloff¹, Stephane Rodriguez², Uyen Huynh-Do¹
¹Berne, ²Rennes / FR
- OC 14 **Human Proximal Tubule Cells Form Functional Microtissues**
Jenny Kürth, Manuela Bieri, Wolfgang Moritz, Olivier Devuyst
Zürich
- OC 15 **A role for hypoxia-inducible cytoglobin in chronic kidney disease?**
Elisa Randi¹, Sara Santambrogio¹, Maja Lindenmeyer¹, Federica Storti¹,
Clemens Cohen¹, Olivier Devuyst¹, Andreas Kistler¹, Roland Wenger¹,
David Hoogewijs²
¹Zürich, ²Essen / DE
- OC 16 **Mechanism of coupling between transcellular sodium transport and paracellular permeability in renal collecting duct cells**
Eric Feraille, Yubao Wang, Isabelle Roth, Thomas Hernandez,
Eva Bernabeu
Geneva

FINDing the balance

Iron and phosphate management in CKD patients

Friday, December 5, 2014, 11.30 – 12.15 h

Room A, Kursaal Interlaken



The future of anemia management in ND-CKD

Prof. Pierre Yves Martin, HUG Genève

Less is more: improving compliance to optimize phosphate control

PD Dr Menno Pruijm, CHUV Lausanne

Chairman: Prof. Dr. med. Rudolf P. Wüthrich

Friday, December 5

From 07.00	Registration	
08.00-09.30	GENERAL ASSEMBLY SGN-SSN	Room A
09.30-09.45	SGN-SSN Publication Award 2014 <i>Chair: Jürg Steiger, Basel</i>	
09.45-10.00	Break	
10.00-11.00	State of the Art Lectures <i>Chairs: Thomas J. Neuhaus, Luzern and Andreas Bock, Aarau</i>	
10.00-10.30	Glomerular albumin handling: Endothelial glycocalyx or podocyte slit diaphragm? Simon Satchell, Bristol (UK)	
10.30-11.00	To beat or not to beat: The cilia in renal diseases Heymut Omran, Münster (D)	
11.00-11.30	Coffee Break – Visit of the Exhibition – Poster Viewing	Exhibition space
11.30-12.15	Satellite Symposia Sponsored by VIFOR <i>Chair: Rudolf P. Wüthrich, Zürich</i>	Room A 
	1. The future of anemia management in ND-CKD Pierre-Yves Martin, Geneva	
	2. Less is more: improving compliance to optimize phosphate control Menno Pruijm, Lausanne	
	Sponsored by BAXTER	Room B 
	Individualization of Hemodialysis Therapy <i>Chair: Michel Burnier, Lausanne</i> Antonio Santoro, Bologna (I)	
12.15-12.30	Break	

AMGEN[®]

invites you to a Scientific Symposium

**Bone Disorders in CKD Patients:
Targets and Therapeutics**

Friday December 5th, 2014
from 12.30 pm – 1.15 pm

Session Chair / Speaker:

Professor Dr Rudolf Wuethrich
USZ, Switzerland

Session Speaker:

Professor Dr René Rizzoli
HUG, Switzerland

AMGEN[®]

AMGEN Switzerland AG, Dammstrasse 21, 6301 Zug, www.amgen.ch

N-CHE-AMG-237-2014-September-P

Friday, December 5

12.30-13.15	Satellite Lunch Symposia Sponsored by AMGEN Bone Disorders in CKD Patients: Targets and Therapeutics <i>Chair: Rudolf P. Wüthrich, Zürich</i> René Rizzoli, Geneva	Room A 
	Sponsored by LABORATOIRE BICHSEL New Advances in PD therapy 1. Advances and literature update in peritoneal dialysis therapy Stephan Segerer, Zürich 2. A new therapeutic platform in peritoneal dialysis therapy Arduino Arduini, Lugano	Room B 
13.15-14.00	Standing Lunch at the Exhibition – Poster Viewing	Exhibition space
14.00-15.00	Oral Parallel Presentations	Room A
14.00-14.45	Hypertension / Minerals / Electrolytes <i>Chairs: Olivier Bonny and Olivier Phan, Lausanne</i> 4 oral presentations	
14.45-15.00	Mini-Lecture Is renal denervation dead? Grégoire Wuerzner, Lausanne	
14.00-14.45	Dialysis <i>Chairs: Stephan Segerer, Zürich and Ann-Kathrin Schwarzkopf, Bern</i> 4 oral presentations	Room B
14.45-15.00	Mini-Lecture Blood pressure on dialysis Florian Buchkremer, Aarau	
15.00-15.30	Coffee Break – Visit of the Exhibition	Exhibition space

NEW ADVANCES IN PD THERAPY

INVITATION SYMPOSIUM 8

5. December 2014, 12.30 – 13.15

Advances and literature update in peritoneal dialysis therapy
Prof. Dr. med. Stephan Segerer

A new therapeutic platform in peritoneal dialysis therapy
Dr. med. Arduino Arduini



bichsel



Laboratorium Dr. G. Bichsel AG, Weissenastrasse 73, 3800 Interlaken

Oral communications

Oral Parallel Presentations

14.00-14.45 Hypertension / Minerals / Electrolytes
Chairs: Olivier Bonny and Olivier Phan, Lausanne

Room A

- OC 17 **Stone formers with the V-ATPase B1 subunit polymorphism p.E161K have a mild urinary acidification deficit with an increased prevalence of CaP containing kidney stones**
Nasser Dhayat¹, John Poindexter², Giuseppe Albano¹, Andreas Pasch¹, Bruno Vogt¹, Orson W. Moe², Daniel Fuster¹
¹Berne, ²Dallas / US
- OC 18 **Dietary phosphate intake increases blood pressure via the NCC cotransporter (NCCR Project)**
Arezoo Daryadel, Isabel Rubio Aliaga, Johannes Loffing, Carsten Wagner
Zürich
- OC 19 **Chronic hydrochlorothiazide treatment up-regulates sodium chloride co-transporter (NCC) expression within urinary exosomes**
Ganesh Pathare¹, Omar A.Z. Tutakhel¹, Mark C. van der Wel¹, Jaap Deinum¹, Jacques W. Lenders², Joost G.J. Hoenderop¹, René J.M. Bindels¹
¹Nijmegen / NL, ²Dresden / DE
- OC 20 **Activation of the transcription factor Nrf2 attenuates the pro-inflammatory response of mouse macrophage following CPP exposure: Potential therapeutic target in vascular calcification (NCCR Project)**
Adam Lister¹, Philippe Marbet¹, Thomas Hammond¹, Ian Copple², Prakash Chandak³, Andreas Pasch³, Christopher Goldring², Alex Odermatt¹
¹Basel, ²Liverpool / GB, ³Bern

Oral communications

Oral Parallel Presentations

14.00-14.45 Dialysis **Room B**
Chairs: Stephan Segerer, Zürich and Ann-Kathrin Schwarzkopf, Bern

OC 21 **Abdominal CT scan in 30 EPS patients prior to surgery: a tool to predict the intraoperative findings?**
Joerg Latus¹, Daniel Kitterer¹, Wolfgang Steuerer¹, Peter Fritz¹, Angela Geissler¹, M. Dominik Alscher¹, Stephan Segerer², Christoph Ulmer¹, Niko Braun¹
¹Stuttgart / DE, ²Zürich

OC 22 **Validation of a specific screening score for sleep disordered breathing in patients undergoing chronic intermittent hemodialysis**
Valentina Forni Ognà¹, Adam Ognà¹, Menno Pruijm¹, Isabelle Bassi¹, Georges Halabi², Thierry Gauthier³, Roberto Bullani⁴, Olivier Phan⁵, Anne Cherpillod¹, Claudine Mathieu¹, Daniel Teta¹, Alexandra Mihalache¹, Michel Burnier¹, Raphaël Heinzer¹
¹Lausanne, ²Yverdon, ³Vevey, ⁴Morges, ⁵Payerne

OC 23 **Trice weekly post-dialysis Cefepime prescription in patients on maintenance hemodialysis**
Filipe Martins, Ould Maouloud Hemett, Veronique Erard, Christian Chuard, Eric Descombes
 Fribourg

OC 24 **Calcitriol concentrations increase significantly in patients on maintenance hemodialysis (HD) receiving long-term cholecalciferol supplementation**
Eric Descombes¹, Benoit Fellay¹, Yann Guillod², Ould Maouloud Hemett¹, Jean-Luc Magnin¹, Gilbert Fellay¹
¹Fribourg, ²Niederwangen

Friday, December 5

15.30-16.30 Final Symposium: The really tough cases Who cares and who pays? **Room A**
Chairs: Andreas Bock, Aarau and Thomas J. Neuhaus, Luzern

15.30-15.40 **The 16 year old Somali immigrant**
 Thomas J. Neuhaus, Luzern

15.40-15.50 **Falling through the social net**
 Mira Hintermann, Aarau

15.50-16.00 **The peritoneal dialysis „quota“ patient**
 Carlo Schönholzer, Lugano

16.00-16.30 **Round table discussion**
 Olivier Bonny, Lausanne
 Ulrich Tanner, Head Tariffss and Performance Controlling Concordia, Luzern and Speakers

16.30 Farewell
 Thomas J. Neuhaus, Luzern; Andreas Bock, Aarau

Poster presentations

Clinical Nephrology

- P 01 **Implementation of nutritional risk screening in daily clinical routine and evaluation of clinical outcome in a tertiary nephrology department**
Spyridon Arampatzis, Vasileios Devetzi, Susanne Gerber, Sibylle Eicken, Bruno Vogt, Uyen Huynh-Do
Berne
- P 02 **Anthropometric measurements and mortality events in chronic kidney disease patients; A decade follow-up in Tehran Lipid and Glucose Study**
Amirali Simforoosh, Reza Mohebi, Farzad Hadaeigh, Fereidoun Azizi
Tehran / IR
- P 03 **FGF_23 or PTH: which comes first in CKD?**
Hans Freudiger
Geneva
- P 04 **Clinical course and long-term outcome in 456 patients with Hantavirus-induced Nephropathia epidemica, Germany, 2001-2012**
Joerg Latus¹, Daniel Kitterer¹, M. Dominik Alscher¹, Stephan Segerer², Niko Braun¹
¹Stuttgart / DE, ²Zürich
- P 05 **New anthropometry-based age- and sex-specific reference values of the urinary 24-h creatinine excretion based on the adult Swiss population**
Valentina Forni Ognà¹, **Adam Ognà**², Menno Pruijm¹, Philippe Vuistiner¹, Belen Ponte¹, Daniel Ackermann³, Luca Gabutti², Nima Vakilzadeh¹, Markus Mohaupt³, Pierre-Yves Martin⁴, Idris Guessous⁴, Antoinette Pechère-Bertschi⁴, Fred Paccaud¹, Murielle Bochud¹, Michel Burnier¹
¹Lausanne, ²Locarno, ³Berne, ⁴Genève
- P 06 **Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy**
Katrin König, Caroline Wehmeier, Helmut Hopfer, Theresia Klima, Min Jeong Kim
Basel

Poster presentations

- P 07 **The changing pattern of postinfectious glomerulonephritis**
Andreas Fischer¹, Walter Arnold¹, Helmut Hopfer²
¹Lucerne, ²Basel
- P 08 **Renal tissue oxygenation as measured with BOLD-MRI in children with vesico-ureteral reflux or a solitary kidney in comparison with healthy controls**
Menno Pruijm¹, Hassib Chehade¹, Maciej Piskunowicz², Bastien Milani¹, Isabelle Bassi¹, Christiane Anex¹, Matthias Stuber¹, Bruno Vogt³, Michel Burnier¹
¹Lausanne, ²Gdansk / PL, ³Berne
- P 09 **Should we care about the sequela of preeclampsia?**
Michael Girsberger¹, Catherine Wiesner², Irene Hösli², Michael Dickenmann²
¹Liestal, ²Basel,
- P 10 **Transjugular renal biopsy in high-risk patients. Experience in 138 cases**
Etienne Monnard, Ruben Lopez-Benitez, Johannes Heverhagen, Dominik Uehlinger, Markus Mohaupt, Spyridon Arampatzis
Berne
- P 11 **Prevalence and predictors of sleep disordered breathing in early stages of chronic kidney disease**
Valentina Forni Ognà, **Adam Ognà**, José Haba Rubio, Nadia Tobback, Murielle Bochud, Raphaël Heinzer
Lausanne
- P 12 **Screening for sleep disordered breathing in ESRD patients scheduled for renal transplantation**
Adam Ognà, **Valentina Forni Ognà**, José Haba Rubio, Nadia Tobback, Isabelle Bassi, Jean Pierre Venetz, Delaviz Golshayan, Ghaleb Nseir, Maurice Matter, Manuel Pascual, Raphaël Heinzer
Lausanne

Poster presentations

- P 13 **Outcome of acute kidney injury in a base hospital in Ticino, Southern Switzerland: Experience of a single center**
Claudia Ferrier, Curzio Solca
Lugano
- P 14 **Extragradient in the electrophoresis of a patient with ARF caused by penicilline-overdosing**
Stefan Kalbermatter¹, Thomas Menter², Helmut Hopfer², Carmen Volken², Denes Kiss¹
¹Liestal, ²Basel
- P 15 **Kidneys On Strike**
Caroline Wehmeier, Julia Wallner, Min Jeong Kim
Basel
- P 16 **A Fribourg case of IgG4-RD (related disease) revealed by IgG4-RKD (related kidney disease), Switzerland**
Ould Maouloud Hemett¹, Eric Descombes¹, Samuel Rotman², Marc Küng¹, Dominique Hennion¹, Daniel Betticher¹, Daniel Hayoz¹
¹Fribourg, ²Lausanne
- P 17 **Hyperprolactinemia in ANCA-Vasculitis**
Ineke Grendelmeier¹, Helmut Hopfer², Denes Kiss¹
¹Liestal, ²Basel
- P 18 **Living without ADAMTS13: Hereditary TTP in a 56-year-old kidney transplant recipient**
Florian Buchkremer¹, Corinne Eschler², Johanna Kremer Hovinga², Andreas Bock¹
¹Aarau, ²Berne
- P 19 **Severe cobalamine deficiency mimicking thrombotic microangiopathy – a sheep in wolf's clothing?**
Christian Bucher, Carola Epp, Isabelle Binet
St. Gallen

Poster presentations

- P 20 **Progressive renal failure after resection of a neuroendocrine tumor of the small intestine**
Michael Girsberger¹, Stefan Kalbermatter¹, Thomas Menter², Helmut Hopfer², Denes Kiss¹
¹Liestal, ²Basel
- P 21 **Renal tubulopathies: rare patients, typical patterns**
Mario Beck¹, Benno Röthlisberger², Thomas J Neuhaus¹
¹Lucerne, ²Aarau
- P 22 **Simply medullary cystic kidney disease?!**
Matthias Zobrist¹, Nilufar Mohebbi²
¹Wetzikon, ²Zürich
- ### Basic Science / Genetics
- P 23 **C3 glomerulonephritis in a patient with Down's syndrome: clinicopathological and genetic findings**
Maria Kosmidis, Albin Schwarz, Patrice Ambühl, Ariana Gaspert
Zürich
- P 24 **Calciprotein particles induce an inflammatory response in macrophages**
Prakash Chandak¹, Rakesh Bijarnia¹, Edward Smith², Andreas Pasch¹
¹Berne, ²Melbourne / AU
- P 25 **The Lymphotoxin β receptor is a therapeutic target in renal inflammation**
Gitta Seleznik¹, Harald Seeger¹, Adrian Papandile², Kai Fu², Urjana Poreci², Julie Czerkowicz², Dania Rabah², Ann Ranger Ranger², Clemens Cohen¹, Maja Lindenmeyer¹, Jin Chen¹, Ilka Edenhofer¹, Hans-Joachim Anders³, Maciej Lech³, Rudolf P Wüthrich¹, Nancy H. Ruddle⁴, Marcus J. Moeller⁵, Jeffrey L. Browning⁶, Judith Bauer³
¹Zürich, ²Cambridge / US, ³Munich / DE, ⁴New Haven / US, ⁵Aachen / DE, ⁶Boston / US

Poster presentations

- P 26 **Comparative effects of aliskiren and hydrochlorothiazide on renal tissue oxygenation in patients with arterial hypertension: a bold MRI study**
Nima Vakilzadeh¹, Menno Pruijm¹, Valentina Forni Ognà¹, Marie-Eve Muller¹, Marc Maillard¹, Matthias Stuber¹, Lucie Hofmann², Bruno Vogt², Michel Burnier¹
¹Lausanne, ²Berne
- P 27 **ENaC activity in collecting ducts modulates NCC in cirrhotic mice**
David Mordasini¹, Dominique Loffing-Cueni², Johannes Loffing², Beatrice Rohrbach¹, Marc Maillard³, Michel Burnier³, Edith Hummler³, Genevieve Escher¹, Bruno Vogt¹
¹Berne, ²Zürich, ³Lausanne
- P 28 **High level of dephospho-uncarboxylated matrix GLA protein (dp-ucMGP) is associated with arterial stiffness and kidney vascular resistance**
Edward Pivin¹, Belen Ponte², Menno Pruijm¹, Daniel Ackermann³, Idris Guessous², Georg Ehret^{2,4}, Cees Vermeer⁵, Jan Staessen⁶, Antoinette Pechère-Bertschi², Fred Paccaud¹, Markus Mohaupt³, Bruno Vogt³, Pierre-Yves Martin², Michel Burnier¹, Murielle Bochud¹
¹Lausanne, ²Geneva, ³Berne, ⁴Baltimore / US, ⁵Maastricht / NL, ⁶Leuven / BE
- P 29 **Identification of renal celltype-specific dysregulation of hypoxia-associated transcripts by transcriptome-based network analysis**
Maja Lindenmeyer¹, Natallia Shved¹, Gregor Warsow², David Hoogewijs¹, Clemens Cohen¹
¹Zürich, ²Greifswald / DE
- P 30 **Improvements in angio- μ CT: What the kidney morphometry will look like**
Ruslan Hlushchuk, Carlos Correa Shokiche, Laura Schaad, Monika Wnuk, Cédric Zubler, Sébastien Barré, Stefan Tschanz, Mauricio Reyes, Valentin Djonov
Berne

Poster presentations

- P 31 **Inhibition of aerobic glycolysis with 2-deoxyglucose retards polycystic kidney disease progression in Han: SPRD rats**
Meliana Riwanto, Sarika Kapoor, Daniel Rodriguez, Ilka Edenhofer, Stephan Segerer, Rudolf P. Wüthrich
Zürich
- P 32 **Inhibition of sodium-glucose cotransporter 2 with Dapagliflozin in Han-SPRD rats with polycystic kidney disease**
Daniel Rodriguez, Sarika Kapoor, Ilka Edenhofer, Stephan Segerer, Meliana Riwanto, Rudolf P. Wüthrich
Zürich
- P 33 **Kappa Light Chains Associated with Fanconi Trigger Aberrations of Endolysosomal Compartment in Proximal Tubule Cells**
Alessandro Luciani¹, Claudia Raggi², Jenny Kürth¹, Vincent Javaugue³, Christophe Ssirac⁴, Olivier Devuyst¹
¹Zürich, ²Brussels / BE, ³Poitiers / FR, ⁴Limoges / FR
- P 34 **Mediator of ErbB2 Induced Cell Motility in Mineral Homeostasis**
Matthias Moor¹, Nancy E. Hynes², Olivier Bonny¹
¹Lausanne, ²Basel
- P 35 **Neuropilin1 as a novel regulator of glomerular basement membrane**
Monika Wnuk, Jean-Baptiste Dubuis, Valentin Djonov
Berne
- P 36 **Oncostatin M receptor is a sensitive and early marker of kidney injury**
Thomas Mueller¹, Barbara Pedrycz², Pang Young², Catherine Compston², Valerie Luyckx², Julie Ho³, Valeria Mas⁴, Lin-Fu Zhu², Donald Grynock², Rachel Khadaroo²
¹Zürich, ²Alberta / CA, ³Manitoba / CA, ⁴Virginia / US
- P 37 **Pathophysiology of Chronic Kidney Disease in Methylmalonic Aciduria (MMA)**
Anke Schumann, Alessandro Luciani, Matthias Baumgartner, Andrew Hall, Olivier Devuyst
Zürich

Poster presentations

- P 38** **Proteomic Signature of Hypertension-induced Damage in the Two-Kidney, One-Clip (2K1C) Rat Model**
Hans-Peter Marti¹, Heidrun Vethe¹, Kenneth Finne¹, Trude Skogstrand¹, Marc Vaudel¹, Bjørn Egil Vikse¹, Michael Hultström², Sandrine Placier³, Andreas Scherer⁴, Olav Tenstad¹
¹Bergen / NO, ²Uppsala / SE, ³Paris / FR, ⁴Kontiolahti / FI
- P 39** **Sex-specific expression of genes involved in uric acid handling in mice**
Muriel Auberson, Candice Stoudmann, Olivier Bonny
Lausanne
- P 40** **Renal sensitivity to orthostatic stress: a comparison of neuro-hormonal and renal hemodynamic responses between obese patients and healthy volunteers**
Nima Vakilzadeh¹, Yann Vuignier², Marc Maillard¹, Eric Grouzmann¹, Vittorio Giusti³, Michel Burnier¹, Grégoire Wuerzner¹
¹Lausanne, ²Valais, ³Broye

Transplantation

- P 41** **ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody positive- RNA negative donor into an anti-hepatitis C virus antibody negative recipient**
Yassine Bouatou, Francesco Negro, Karine Hadaya
Geneva
- P 42** **Distinct radiological CT-patterns of Pneumocystis jirovecii pneumonia between Renal transplant recipients and HIV-positive patients**
Spyridon (Spiros) Arampatzis, Lukas Ebner, Andri Rauch, Hansjakob Furrer, Stefan Weiler, Johannes Heverhagen, Uyen Huynh-Do, Andreas Christe
Berne

Poster presentations

- P 43** **Non-invasive kidney fibrosis assessment using optimized diffusion MRI**
Lena Berchtold, Iris Friedli, Lindsey Crowe, Karine Hadaya, Solange Moll, Pierre-Yves Martin, Jean-Paul Vallée, Sophie de Seigneux
Geneva
- P 44** **Outcome of transitional cell cancer in renal transplant recipients**
Felix Burkhalter, Peter Ardelt, Jan Ebbing, Gernot Bonkat, Jürg Steiger, Alexander Bachmann
Basel
- P 45** **Outcomes at 3-years in EBV+ Recipients of Deceased Donor Kidneys from Two Randomized Trials (BENEFIT and BENEFIT EXT) Comparing Belatacept vs Cyclosporine**
Ferdinand Mühlbacher¹, Antoine Durrbach², Sander Florman³, José Medina Pestana⁴, Mary Beth Harler³, Christian Larsen⁵
¹Vienna / AT, ²Le Kremlin-Bicêtre / FR, ³New York / US, ⁴Sao Paulo / BR, ⁵Atlanta / US
- P 46** **Outcomes at 3-years in EBV+ Recipients of UNOS Criteria ECD Kidneys from a Randomized Trial (BENEFIT-EXT) Comparing Belatacept vs Cyclosporine**
Ferdinand Mühlbacher¹, Antoine Durrbach², Sander Florman³, José Medina Pestana⁴, Martin Polinsky³, Bernard Charpentier¹
¹Vienna / AT, ²Le Kremlin-Bicêtre / FR, ³New York / US, ⁴Sao Paulo / BR
- P 47** **Prevention of bone mineral density (BMD) loss after kidney transplantation with the RANK ligand inhibitor denosumab (POSTOP study): baseline data, biomarker response and initial safety**
Marco Bonani, Thomas Fehr, Thomas Mueller, Markus Blum, Jens Brockmann, Diana Frey, Rudolf Wüthrich
Zürich
- P 48** **Risk stratification for rejection and infection after kidney transplantation**
Pietro Cippà¹, Marc Schiesser¹, Teun Van Gelder², Nicolas Müller¹, Claude Cao¹, Corrado Bernasconi¹, Thomas Fehr¹
¹Zürich, ²Malmö / SE

Poster presentations

- P 49** **Role of lymphotoxins in renal allograft rejection**
Harald Seeger¹, Gitta Seleznik¹, Maja Lindenmeyer¹, Clemens Cohen², Carsten Jäckel², Peter Nelson², Jin Chen¹, Ilka Edenhofer¹, Nicolas Kozakowski³, Heinz Regele³, Georg Böhmig³, Judith Bauer², Rudolf P Wüthrich¹, Thomas Fehr⁴, Mathias Heikenwälder², Stephan Segerer¹
¹Zürich, ²Munich / DE, ³Vienna / AT, ⁴Chur
- P 50** **Sarcopenic obesity in male renal transplant recipients**
Vasileios Devetzis, Uyen Huynh-Do, Spyridon Arampatzis – Berne
- P 51** **Severe calciphylaxis in a renal transplant patient after denosumab administration: causal relationship or mere coincidence?**
Argyrios Georgalis, Katja Ivanova, Vera Frauenknecht, Patrizia Amico, Jürg Steiger
Basel
- P 52** **The inflammatory burden determined by urinary CXCL10 chemokine levels predicts long-term renal allograft outcome**
Patricia Hirt-Minkowski¹, Julie Ho², Ang Gao², Patrizia Amico¹, Michael T. Koller¹, Helmut Hopfer¹, David Rush², Peter Nickerson², Stefan Schaub¹
¹Basel, ²Manitoba / CA
- P 53** **What should the post-transplant creatinine be? An approach to better assess kidney transplant function**
Thomas Mueller¹, Scott-Oliver Grebe², Riyad Ylsehli³, Valerie Luyckx⁴, Zija Jacaj⁵
¹Zürich, ²Witten / DE, ³Riyadh / SA, ⁴Edmonton / CA, ⁵Athabasa / CA

Hypertension / Mineral / Electrolytes

- P 54** **A rare cause of kidney stones or just coincidence?**
Harald Seeger, Nilufar Mohebbi – Zürich
- P 55** **Renal Stone Clinic – How do patients perceive our explanations and recommendations?**
Bernhard Hess – Zürich

Poster presentations

- P 56** **FGF23 and markers of phosphate and calcium homeostasis in subjects with preserved renal function**
Nasser Dhayat¹, Daniel Ackermann¹, Menno Pruijm², Belen Ponte³, Idris Guessous², Philippe Vuistiner², Georg Ehret³, Fred Paccaud², Markus Mohaupt¹, Michel Burnier², Antoinette Pechère-Bertschi³, Pierre-Yves Martin³, Murielle Bochud², Bruno Vogt¹, Daniel Fuster¹
¹Berne, ²Lausanne, ³Geneva
- P 57** **Proton-pump inhibitor associated hypomagnesemia: a systematic review**
Sebastiano A.G. Lava¹, Simone Janett², Giacomo D. Simonetti², Barbara Goeggel Simonetti², Mario G. Bianchetti²
¹Berne, ²Bellinzona
- P 58** **Why muscle cramps occur at night: Circadian rhythm and factors associated with fractional excretion of magnesium in a population based study**
Daniel Ackermann¹, Menno Pruijm², Belen Ponte², Idris Guessous³, Georg Ehret^{3,4}, Bernhard Dick¹, Claudia D'uscio¹, Genevieve Escher¹, Markus Mohaupt¹, Michel Burnier², Pierre-Yves Martin³, Fred Paccaud², Bruno Vogt¹, Olivier Devuyst⁵, Murielle Bochud²
¹Berne, ²Lausanne, ³Geneva, ⁴Baltimore / US, ⁵Zürich
- P 59** **Angiotensinergic innervation of the human right atrium, atrial angiotensins and implications for baroreceptor control of blood pressure**
Jürgen Bohlender¹, Jürg Nussberger², Hendrik Tevaearai¹, Hans Imboden¹
¹Berne, ²Lausanne
- P 60** **Cytochrome P450 3A 4 / 5 (CYP3A4 / 5) activity is associated with white coat blood pressure in a Swiss population based study (SKIPOGH Study)**
Yassine Bouatou¹, Belen Ponte¹, Daniel Ackermann², Menno Pruijm³, Idris Guessous¹, Georg Ehret^{1,4}, Fred Paccaud³, Antoinette Pechère-Bertschi¹, Bruno Vogt², Michel Burnier³, Markus Mohaupt², Pierre-Yves Martin¹, Murielle Bochud³
¹Geneva, ²Berne, ³Lausanne, ⁴Baltimore / US

Poster presentations

P 61 Taste acceptability of pulverized brand-name and generic drugs containing amlodipine or candesartan
Sebastiano A.G. Lava¹, Peter Uestuener², Alessandra Ferrarini², Maristella Santi², Chiara Mardegan², Mario G. Bianchetti², Giacomo D. Simonetti²
¹Berne, ²Bellinzona

P 62 Impact of uninephrectomy on body L-arginine homeostasis and blood pressure control (NCCR project)
Samyuktha Pillai, Ralph Fingerhut, François Verrey – Zürich

Dialysis

P 63 A rare case of peritoneal dialysis associated peritonitis with *Sphingomonas koreensis*
Julia Wallner, Felix Burkhalter – Basel

P 64 Histological and clinical findings in patients with post-transplantation and classical encapsulating peritoneal sclerosis: a European multicenter study
Joerg Latus¹, Daniel Kitterer¹, Meelad Habib², Mario Korte³, Christoph Ulmer¹, Peter Fritz¹, Simon Davies⁴, Mark Lambie⁵, M. Dominik Alscher¹, Michiel Betjes², Stephan Segerer⁶, Niko Braun¹
¹Stuttgart / DE, ²Rotterdam / NL, ³Dordrecht / NL, ⁴Keele / GB, ⁵Stoke-on-Trent / GB, ⁶Zürich

P 65 Platelet-derived growth factor receptor β (PDGFR β) expression in human peritoneum
Stephan Segerer¹, Harald Seeger¹, Niko Braun², Joerg Latus², M. Dominik Alscher², Peter Fritz², Ilka Edenhofer¹, Dagmar Biegger², Maja Lindenmeyer¹, Rudolf P. Wüthrich¹
¹Zürich, ²Stuttgart / DE

P 66 Demographic characteristics of maintenance hemodialysis (HD) patients in Switzerland
Rebecca Winzeler¹, Hans-Rudolf Rätz², Denes Kiss³, Thomas Kistler⁴, Agnes Kneubühl⁵, Johannes Trachsler⁵, Marco Miozzari⁶, Patrice Ambühl¹
¹Zürich, ²Baden, ³Liestal, ⁴Winterthur, ⁵Lachen, ⁶Schaffhausen

Poster presentations

P 67 Assessment of lean tissue mass (LTM) in maintenance hemodialysis (HD) patients
Rebecca Winzeler¹, Hans-Rudolf Rätz², Denes Kiss³, Thomas Kistler⁴, Agnes Kneubühl⁵, Johannes Trachsler⁵, Marco Miozzari⁶, Patrice Ambühl¹
¹Zürich, ²Baden, ³Liestal, ⁴Winterthur, ⁵Lachen, ⁶Schaffhausen

P 68 Handgrip strength and mortality in a hemodialysis (HD) cohort
Rebecca Winzeler¹, Hans-Rudolf Rätz², Denes Kiss³, Thomas Kistler⁴, Agnes Kneubühl⁵, Johannes Trachsler⁵, Marco Miozzari⁶, Patrice Ambühl¹
¹Zürich, ²Baden, ³Liestal, ⁴Winterthur, ⁵Lachen, ⁶Schaffhausen

P 69 Is the nutritional risk screening (NRS) score a useful tool to predict changes in lean tissue mass of maintenance hemodialysis (HD) patients?
Rebecca Winzeler¹, Hans-Rudolf Rätz², Denes Kiss³, Thomas Kistler⁴, Agnes Kneubühl⁵, Johannes Trachsler⁵, Marco Miozzari⁶, Patrice Ambühl¹
¹Zürich, ²Baden, ³Liestal, ⁴Winterthur, ⁵Lachen, ⁶Schaffhausen

P 70 Baclofen toxicity in a dialysis patient
Theodora Fragkou, Konstantina Goula, Ourania Drakoulogkona Patras / GR

P 71 Comparison of sodium conductivity prescription and dialysate sodium concentration with three different hemodialysis (HD) monitors: not all the monitors are equal.
Eric Descombes, Benoit Fellay, Erwin Riedo, Ould Maouloud Hemett, Jean-Luc Magnin, Gilbert Fellay
Fribourg

P 72 The association between ultrafiltration volume and difference of the pre- and post-dialysis hemoglobin levels in maintenance hemodialysis patients
Michael Moeddel
Zürich


Poster presentations

- P 73 Large variations in pulse wave velocity and reflection patterns occur during a hemodialysis session and are not related to the degree of ultrafiltration
Menno Pruijm¹, Daniel Teta¹, Corina Rotaru¹, Valentina Forni Ognal¹, Georges Halabi², Bernard Waeber¹, Michel Burnier¹, Francois Feihl¹
¹Lausanne, ²Yverdon
- P 74 Poor correlation of 44h blood pressure measurements with in-center blood pressure in hemodialysis patients
Florian Buchkremer, Andreas Bock
 Aarau
- P 75 First experience in Switzerland of the HeRO[®] graft for arterio-venous access for hemodialysis
Sebastien Deglise, Thomas Holzer, Anne Cherpillod, Sebastien Kissling, Daniel Teta, François Saucy, Francesco Doenz, Beat Von Albertini, Jean-Marc Corpataux
 Lausanne
- P 76 Fistula First Initiative: Yes, we can
Celine Dubuis¹, Sebastien Deglise¹, Sotirios Popeskou², Sebastien Kissling¹, Francesco Doenz¹, François Saucy¹, Daniel Teta¹, Jean-Marc Corpataux¹
¹Lausanne, ²Lugano
- P 77 Is supplementation of water soluble vitamins justified in chronic hemodialysis patients?
Thomas Hochgruber, Andreas Jehle, Michael Dickenmann, Theresia Klima
 Basel
- P 78 Sclerostin and other circulating bone remodeling markers in hemodialysis patients
Albina Nowak¹, Ferruh Artunc², Andreas Serra¹, Emily Pollock¹, Pierre-Alexandre Kraysenbuehl³, Christian Mueller⁴, Björn Friedrich⁵
¹Zürich, ²Tübingen / DE, ³Uznach, ⁴Basel, ⁵Herrenberg / DE

City map of Interlaken



Plan



Exhibitors

Firm	Booth
Abbvie	2
Amgen	17
Astellas	3
B. Braun	21
Bard Medica	11
Baxter-Gambro Renal	7
Bracco	9
Euromed	14
Forni	22
Fresenius	18
Dr. G. Bichsel	19
MCM Medsys	23
MSD	4
Nephro-Medical	24
Novartis	13
Opo Pharma	8
Otsuka	10
Pfizer	12
Pro Farma	5
Sanofi	1
Shire	20
The Binding Site	16
Theramed	15
Vifor	6

Sponsored symposia in alphabetical order



Amgen Switzerland AG, Zug
Parallel Satellite Lunch Symposium
Friday, December 5, 2014
12.30-13.15 / Room A



Baxter-Gambro Renal, Volketswil
Parallel Satellite Lunch Symposium
Thursday, December 4, 2014
12.30-13.15 / Room A



Baxter-Gambro Renal, Volketswil
Parallel Satellite Symposium
Friday, December 5, 2014
11.30-12.15 / Room B



Fresenius Medical Care (Schweiz) AG, Oberdorf
Parallel Satellite Lunch Symposium
Thursday, December 4, 2014
12.30-13.15 / Room B



Laboratorium Dr. G. Bichsel AG, Unterseen
Parallel Satellite Lunch Symposium
Friday, December 5, 2014
12.30-13.15 / Room B



Novartis Pharma Schweiz AG, Rotkreuz
Satellite Symposium
Thursday, December 4, 2014
15.30-16.15 / Room A



Vifor Pharma, Villars-sur-Glâne
Parallel Satellite Symposium
Friday, December 5, 2014
11.30-12.15 / Room A

Advertisement

Abbvie AG
Amgen Switzerland AG
Baxter-Gambro Renal
Fresenius Medical Care (Schweiz) AG
Laboratorium Dr G. Bichsel AG
Novartis Pharma Schweiz AG
Pro Farma AG
Vifor Pharma

Association

Association pour l'Information et la Recherche sur les maladies rénales Génétiques (AIRG)



Kind thanks to the municipality of Interlaken for its financial support and welcome



Thursday, December 4

Ballsaal / Room B

CONGRESS DINNER

17.30-19.00	Main Poster Session – Apéro	Poster area
19.30	Congress Dinner – Poster Prize Awards	Ballsaal



The magnificent rooms of the Casino Kursaal Interlaken date from the 19th century and provide a perfect setting for the Congress Dinner of the Swiss Society of Nephrology.

You will enjoy this unique atmosphere, combined with first-class service and excellent cuisine.

We await your reservation with pleasure when registering online on www.meeting-com.ch. Pre-reservation is highly recommended. Additional tickets will be available at the registration desk on a first come first served basis.

Price: CHF 70.00/ticket

Congress Centre Kursaal Interlaken – Strandbadstrasse 44 – 3800 Interlaken

Save the date: SGN-SSN congress 2015

We would like to invite you to the

**47th Annual Meeting
of the Swiss Society of Nephrology (SGN-SSN)
on December 3-4, 2015 – Congress Center Basel**



Please save the dates of December 3-4, 2015 !

We look forward to welcoming you in Basel next year !

NEPHRO
SWISS SOCIETY OF NEPHROLOGY
www.swissnephrology.ch

Schweizerische Gesellschaft für Nephrologie
Soci t  Suisse de N phrologie
Societ  Svizzera di Nefrologia

Kind thanks to all our sponsors

abbvie

AMGEN®

 **astellas**
Leading Light for Life

B|BRAUN
SHARING EXPERTISE

BAIRD

Baxter
 **GAMBRO®**

bichsel


BRACCO
LIFE FROM INSIDE

 **EUROMED Swiss**
Group Medical Distribution Services

fm **forni medical gmbh**

 **FRESENIUS
MEDICAL CARE**

 **MCM MEDSYS AG**

Kind thanks to all our sponsors

 **MSD**

 **Nephro-Medical**
Schweiz GmbH

 **NOVARTIS**

 **OpoPharma**


Otsuka

Pfizer


PRO FARMA


SANOFI

 **Shire**

Binding Site 
THE BINDING SITE


theramed ag
medizinprodukte

 **Vifor Pharma**

SELEKTIV VDR AKTIVIEREN¹



Studien von Zemplar[®] zeigen

- effizientes Erreichen des iPTH-Zielbereichs²
- signifikant weniger Hypokalzämien² (vs. Cinacalcet)
- signifikant weniger Hyperkalzämien³ (vs. Calcitriol)
- signifikante Senkung der Proteinurie⁴
- positive Beeinflussung des Kardiorenalen Syndroms⁵

Für Ihre SHPT-Patienten der CKD-Stadien 3, 4
und bei chronischer Häm- und Peritonealdialyse⁶

ZEMPLAR[®]
(PARICALCITOL) KAPSELN & INJEKTION
Selektiv | Effektiv | Protektiv

1. Cannata JB, Navez-Diaz M. The Role of Paricalcitol in Chronic Kidney Disease. *European Nephrology*. (2011) 5(2):82-90. 2. Ketteler M et al.: Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: results of the IMPACT SHPT study. *Nephrol Dial Transplant*. (2012) 27:3270-3278. 3. Sprague SM et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. *Kidney International*. (2003) 63:1483-1490. 4. De Nicola L et al.: Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. *BMC Nephrology*. (2012) 13:150-7. 5. Ronco C, Cozzolino M: Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. *Heart Fail Rev*. (2011) 17(2):211-20. 6. Arzneimittel-Fachinformation für Zemplar[®]: www.swissmedinfo.ch. Stand der Informationen: Ampullen, April 2011; Kapseln, Februar 2014.

Zemplar[®] Injektionslösung: IA: Sekundärer Hyperparathyreoidismus bei Patienten mit terminaler Niereninsuffizienz und chronischer Hämodialyse. **DA:** Intravenöse Bolusinjektion während der Dialyse; maximal alle zwei Tage. Anfangsdosis richtet sich nach den Basis-Serumspiegeln des intakten Parathyroidhormons (iPTH): Initialdosis (μg) = iPTH Basis-Serumspiegel (pg/ml) / 80. Falls keine zufriedenstellende Reaktion beobachtet wird, kann die Dosis in Schritten von 2–4 μg Paricalcitol in jeweils zwei- bis vierwöchigen Intervallen erhöht werden. Während Dosisanpassung engmaschig Überwachung von Serum-Kalzium und -Phosphor. Falls Serum-Kalzium über Norm ansteigend oder $\text{Ca} \times \text{P} > 65 \text{ mg}^2/\text{dl}^2$, Dosisreduktion oder Therapieunterbruch. **KI:** Nicht bei Patienten mit Hyperkalzämie oder Anzeichen von Vitamin D Toxizität verabreichen. Nicht bei Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe. **IN:** Spezifische Interaktionsstudien wurden nicht durchgeführt. Nicht gleichzeitig mit Heparin, phosphathaltigen Arzneimitteln oder Vitamin D verwandten Präparaten einnehmen. Vorsicht bei Gabe von Paricalcitol zusammen mit Digitalis-Präparaten, Ketokonazol sowie anderen starken CYP3A-Hemmern, Thiazid-Diuretika oder kalzium-, magnesium- und aluminiumhaltigen Arzneimitteln. **UW:** Häufig: Hyperkalzämie, Kopfschmerzen, Dysgeusie, gastrointestinale Blutung, Diarrhö, Verstopfung, Fieber, Schüttelfrost und Schmerzen an der Einstichstelle. **P:** 5 Ampullen (je 1 ml) à 2 bzw. 5 μg Paricalcitol. Liste B. Kassenzulässig. Limitatio beachten. **Zemplar[®] Kapseln:** IA: Behandlung des sekundären Hyperparathyreoidismus bei Patienten mit chronischer Niereninsuffizienz in der Präldialysephase (chronic kidney disease [CKD] Stufen 3 & 4), sowie Behandlung des sekundären Hyperparathyreoidismus bei Patienten mit terminaler Niereninsuffizienz (CKD Stufe 5) und chronischer Hämodialyse oder Peritonealdialyse. **DA:** 1x pro Tag entweder täglich oder 3x die Woche, d.h. jeden 2. Tag. CKD Stufen 3 & 4: Initialdosis basierend auf den Basis-Serumspiegeln des intakten Parathyroidhormons (iPTH): Anfangsdosis bei iPTH < 500 pg/ml: 1 μg 1x tgl. oder 2 μg 3x pro Woche; bei > 500 pg/ml: 2 μg 1x tgl. oder 4 μg 3x pro Woche; Dosis titration: Dosierung individuell dem iPTH anpassen. CKD Stufe 5: Initialdosis basierend auf den Basis-Serumspiegeln des iPTH (pg/ml) / 60; Dosis titration: Dosis (μg) = aktueller iPTH (pg/ml) / 60. Zu Beginn der Therapie, während der Dosisanpassungs-Phasen und bei gleichzeitiger Verabreichung von starken Cytochrom P450 3A Inhibitoren, Serumspiegel von Calcium und Phosphor engmaschig überwachen und Empfehlungen bei $\text{Ca} \times \text{P} > 55 \text{ mg}^2/\text{dl}^2$ (CKD 3&4) bzw. $> 70 \text{ mg}^2/\text{dl}^2$ (CKD 5) beachten. Zemplar Kapseln können unabhängig von den Mahlzeiten eingenommen werden. **KI:** Nicht bei einer Hyperkalzämie oder Anzeichen von Vitamin D-Toxizität verabreichen. Nicht bei Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe. **IN:** Nicht gleichzeitig mit phosphathaltigen Arzneimitteln oder Vitamin D verwandten Präparaten einnehmen. Vorsicht bei Gabe von Paricalcitol zusammen mit Digitalis-Präparaten, Ketokonazol sowie anderen starken CYP3A-Hemmern, Thiazid-Diuretika oder kalzium-, magnesium- und aluminiumhaltigen Arzneimitteln. Mögliche Beeinträchtigung der Absorption von Paricalcitol mit Arzneimitteln wie Cholestyramin, welche die intestinale Absorption von fettlöslichen Vitaminen beeinflussen. **UW:** Häufig: CKD Stufen 3 & 4: abdominale Beschwerden und Ausschlag. CKD Stufe 5: Hyperkalzämie, Hypokalzämie, verminderter Appetit, Benommenheit, Diarrhö, gastro-oesophagealer Reflux, Akne und Spannungen in der Brust. **P:** je 28 Kapseln à 1 bzw. 2 μg Paricalcitol. Liste B. Kassenzulässig. Limitatio beachten. **ZI:** AbbVie AG, Neuhofstrasse 23, CH-6341 Baar, Tel. 041 399 15 00. Ausführliche Informationen, siehe Arzneimittel-Fachinformation: www.swissmedinfo.ch.